In support of this notion, mouse genetic studies show that while deletion of FOXO1 alone is insufficient to induce tumorigenesis in the mouse prostate, FOXO1 loss cooperates with TMPRSS2-ERG fusion, the most frequent genetic alteration in human prostate cancers to promote tumorigenesis 23. The gene discussed is FOXO1; the disease is prostate carcinoma.